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WELCOME
This year’s Children’s Mercy Cancer
Center Annual Report focuses
on what, until now, has been
a far-off distant future dream –
Cancer Genomics. IT IS HERE! And
now cancer genomics is rapidly
redefining our understanding of
cancer, and in turn our treatment of
cancer.
It was not too long ago that
many thought cancer might be
caused by viruses. We now know
that cancer is, in fact, the result
of one of our own cells gone
awry—like a copy machine stuck
on copy. The resulting mistakes
in our instructions, better known
as our genes, are mutations that
drive these cancer cells to divide
uncontrollably.
The result is these cancer cells take
over the space our normal cells
and organs need to do their jobs,
spreading and wreaking damage
throughout the body. Much of our
new understanding of this process
is being generated by our own
researchers here at Children’s
Mercy. Their work clearly shows
that what may appear to be similar
between adults and children is not.
Cancer has vastly different origins,
different mutations, and different
paths in children as compared to
adults.

4

In adults, it generally takes decades
of cumulative mutations to finally
result in enough change in those
genes to turn the cell into a cancer
cell. But in children, the mutations
are few. Sometimes just a single
mutation is powerful enough to turn
a cell cancerous, and can do so in
a child in a much shorter time span,
even as young as a newborn.
In my 30-plus years in the field
of childhood cancer, I have seen
many changes resulting in many
improvements for our young
patients. Yet, in just the past five
to 10 years, with the advent of
genomics, there has been an
explosion of new discoveries
resulting from the critical research
labs in cancer centers and
universities, like those in the
Children’s Mercy Research Institute,
and from the bedsides of children
fighting the battle for their lives.
At times it seems like we are
stepping out of a thick, dark forest
into a bright, vast clearing that
illuminates the causes of, and
the therapeutic approaches for,
cancer. It is such a bright light
that we are still adjusting to it. But
we are now seeing our future in
the therapy for childhood cancer
more clearly. We are so fortunate
to have these capabilities here at
Children’s Mercy. Both the research

focus and clinical application of
this new medical approach in our
Cancer Genomics program benefits
children in our region, and as you’ll
read, nationally and internationally.
In this journey of better
understanding cancer, and
particularly childhood cancer,
we have entered a new era of
discovery that is creating a new
era of understanding. With the
research and clinical application
that is ongoing in the Children’s
Mercy Cancer Genomics Program
and worldwide, we will be, in the
coming few years, learning how to
better apply this understanding with
more precise and rational therapy.
We are already seeing in select
cancers that this is proving to be a
safer way to achieve higher cure
rates for our children. Join us in the
following pages as we describe
these research discoveries and
how we are starting to apply them
for our children who have cancer.
But stay tuned, this is only the
beginning.

ALAN S. GAMIS, MD, MPH
Associate Division Director, Section of
Oncology; Professor of Pediatrics, University
of Missouri-Kansas City School of Medicine;
Clinical Professor of Pediatrics, University of
Kansas School of Medicine
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CANCER REGISTRY 20I8
The Cancer Registry at
Children’s Mercy Kansas
City plays a vital part in the
surveillance of cancer in
our pediatric population.
The Cancer Registry is a
HIPAA-compliant confidential
database comprised of
malignant cancers, benign
brain tumors and other specified
benign tumors. The database
is operated under the guidance
of the Cancer Care Committee.
Data collected, which includes
diagnosis, treatment, recurrence
and survival, is standardized for
state and national comparisons.

Following each patient’s cancer
status is a very important part of
Cancer Registry data collection.
Knowing outcomes of each cancer
patient can assist care providers
with determining best treatment
methods and long-term effects
of cancer treatment. Therefore,
follow-up letters inquiring about
a patient’s cancer status are sent
out yearly. Parents and older
patients are encouraged to contact
the registry by secure email at
cancerregistry@cmh.edu to discuss
follow-up.

CASES
WITHMOLECULAR
MOLECULAR TESTING
CASES
WITH
TESTING
35

During 2018, the Cancer Registry
added 209 patients to the
database. Of these patients,
there were 188 patients who were
diagnosed with malignancies and
benign central nervous system
tumors. There were 21 patients
added to the registry as having
benign reportable conditions.
These conditions are collected
at the request of the Cancer
Care Committee for surveillance
purposes and are not required to
be reported outside our facility.
Please see the frequency by
diagnosis chart for a breakdown of
cancers.
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Patients added to the
Cancer Registry
database during 2018.
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Acute
Lymphoblastic
Leukemia

Acute
Myeloid
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Non-Hodgkin
Lymphoma

Hodgkin
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Kidney
Tumors

Bone
Tumors

Neuroblastoma
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Patients added to the
Cancer Registry
as having benign
reportable conditions
during 2018.
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Nearly 100 molecular tests were performed on cancer samples in 2018. Testing
revealed important molecular changes in many genes including FLT3, NPM1,
BRAF, BCOR, NRAS and SMO. This information helped guide patient diagnoses,
prognoses and therapies.
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When it comes to cancer, as with many pediatric diseases, children are
not simply little adults. Unlike adult cancer, childhood cancers are not
typically associated with numerous genetic alterations. As a result, the
molecularly targeted therapies designed to treat adults with cancer are
not often beneficial to children. Further, childhood cancer is rare and
many of the mutations discovered in the cancer cells are actually in the

FORGING THE PATH OF

germline, within all cells in the body.

PEDIATRIC
CANCER
GENOMICS

In addition, genomic research has taught us that pediatric cancers are
diverse and that each patient’s case is unique. This presents a major
challenge in breaking down the data in a meaningful way to guide and
individualize treatments. The Children’s Mercy Cancer Center Genomics
Program, established in 2014, consists of a team of clinicians and
researchers with the common goals of incorporating genomics into our
everyday clinical treatments and research programs to improve the
outcomes for our patients.
The Cancer Genomics Program
serves as a bridge between the
Genomic Medicine Center and
the Division of Hematology/
Oncology/Blood and Marrow
Transplant at Children’s Mercy.
Program members include
pediatric oncologists, molecular
and anatomic pathologists,
cytogeneticists, clinical
geneticists, genetics counselors,
bioinformaticians, and other subspecialists with particular interests
in cancer diagnostics and research.
Erin Guest, MD

Genomic medicine traverses many
different disciplines and the Cancer
Genomics Program is designed to
intertwine with and support the
genomics needs of all of the other
cancer center programs, including
the Leukemia and Lymphoma
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Program, the Brain Tumor Program,
the Adolescent and Young
Adult Program, Experimental
Therapeutics, Stem Cell Transplant,
and many more.
The Cancer Genomics Program
supports clinical genomics testing
for direct patient care, a variety
of research efforts in genomics,
and translational projects that
tie patient outcomes to genomic
testing. In its research functions,
the program relies upon the
Children’s Mercy Research Institute
(CMRI) for support. In addition, the
Children’s Mercy Cancer Center,
the CMRI and the Cancer Genomics
Program are all fortunate to have
incredibly generous philanthropic
donors who have made this work
possible.
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We have grown our clinical cancer genomics capabilities
extensively, and we now perform most sequencing testing
in our on-site Genomic Medicine Center lab. It’s important to
note that the interpretation of cancer genomics test results
is challenging and requires extensive knowledge and skill.
Genetic mutations, also known as variants, that are
specific to cancer cells are often not present uniformly
within the cancer. Sometimes variants are at such a
low level that it can be difficult to distinguish a real
mutation from the background error rate inherent to the
sequencing process.

childhood cancer predisposition
syndromes have established
guidelines for cancer screening
and early detection, which have
been shown to result in better
chances of survival.
We work closely with our clinical
genetics providers to accomplish
testing, counseling, and screening
when appropriate. Our Surveillance
for Predisposition to Tumors (SPoT)

Our specialized team of molecular oncologists
interprets each child’s cancer sequencing result in
the context of his/her cancer diagnosis and germline
sequencing data. Next, we review the results in our
multidisciplinary molecular tumor board. The child’s
oncologist discusses the clinical diagnosis and the
team of experts reviews the sequencing findings to
determine if other therapies might be beneficial. In
doing so, we take an individualized approach to
every patient and we incorporate all available data
into the treatment recommendation.
As mentioned above, germline mutations play an
important role in the development of childhood
cancer. Germline mutations may be inherited
or may occur de novo, during the child’s
early development. For this reason, genetic
counseling and testing are especially important
to determine if a germline mutation contributed
to the child’s risk of developing cancer, and
to discuss the risk to other family members,
including siblings.
Certain germline mutations are associated
with known risks for specific, often very
rare types of cancer. For example, germline
mutation of the TP53 gene results in Li
Fraumeni syndrome, with increased risks for
solid tumors, brain tumors, and leukemias
throughout life, from early childhood to
adulthood. Li Fraumeni and many other
10

clinic is dedicated to providing a
home for patients to coordinate the
recommended screening tests. We
see patients annually for visits and
work closely with their primary care
doctors and other subspecialists to
ensure that each child receives the
recommended care based on his/
her diagnosis.
Research is critical to gain
understanding of the significance
of sequencing results. To build
a robust foundation of new
knowledge, the Cancer Genomics
Program has partnered with

the Children’s Mercy Oncology
Biorepository, also known as the
Tumor Bank, to sequence every
single cancer case in the bank.
Patients and their parents are
given the opportunity to donate
blood, bone marrow and tumor
tissue remaining after a biopsy to
the Tumor Bank. The specimens
are taken to the CMRI for isolation
of DNA, RNA, live cells and other
components, and then portions
are transferred to the Genomic
Medicine
Center for
sequencing.
The patient’s
personal
identifiers
are removed.
The result
is a broad
data set that
includes
most of the
cancers
diagnosed
at Children’s Mercy, giving us the
ability to compare changes in the
cancer cells from diagnosis to
relapse, if relapse occurs.
Investigators can utilize the data
to design and test new treatment
approaches on the banked cells.
The de-identified sequencing data
will soon be shared in an online
public database, empowering
collaborative world-wide sharing
of cancer genomics data toward
a common goal of improving
molecularly targeted treatments.
In addition to our sequencing

of Tumor Bank clinical samples,
our Cancer Genomics Program
supports a variety of other cancerspecific research projects. Our
largest project so far has involved
orthogonal sequencing of leukemia
samples from infants with acute
lymphoblastic leukemia (ALL).
This sequencing work has
identified mutations gained at
relapse in infants with ALL who are
enrolled in a Children’s Oncology
Group clinical trial. Ongoing work
with additional infant ALL samples
is looking at epigenetic changes
within the patients’ cells before and
after treatment with azacitidine.
To date, we have collaborated
with researchers at Johns Hopkins
University, Children’s Hospital
of Philadelphia, The University
of Kansas, Children’s National
Medical Center, among other
institutions, and we welcome new
research partnerships.
Our vision for the Cancer Genomics
Program is that every child with
cancer is given the opportunity
to participate in clinical testing
and to contribute to research.
Although the field of cancer
genomics is still relatively new,
this information-gathering phase
is a critical step and we consider
it important to broadly study and
compare sequencing results across
all childhood cancer types. Our
program is poised to lead the
way in generating and sharing
data, improving outcomes for our
patients now and in the future.
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patients, this includes sequencing the genome of both
their cancer cells (to look for changes that drive tumors),
as well as their healthy cells (to look for inherited
changes that increase the risk of developing cancer).
Testing patients in-house allows us to not only offer
this dual sequencing but also to do it via the most
comprehensive method of sequencing available,
whole genome. Many other laboratories offer
sequencing of a few cancer-related genes and
sequence only the tumor sample by itself. Such
testing makes it difficult to identify which genetic
changes are truly specific to a tumor versus those
that may be inherited and increase risk of cancer
for a patient and their family.

The Human Genome
Project—an international scientific
research collaboration that undertook sequencing of the entire human
genome—took 13 years, 20 laboratories across the globe, and roughly 3 billion dollars to complete.
In this context, it is astounding to consider that “local” genome sequencing performed by a hospital laboratory
could even be a possibility, but, amazingly, less than a decade after completion of the Human Genome
Project, it became very much a reality!
Today, multiple human genomes
can be sequenced by a single
laboratory in just a few days at a
technical cost of about $1,000 per
genome. Of course, this cannot
be done in just any laboratory.
It requires investment in a stateof-the-art facility, the presence of
special sequencing equipment,
availability of significant
computational resources, and
hiring of specialized personnel to
manage the entire process.
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We are fortunate that Children’s
Mercy Kansas City was at the
forefront of this movement,
investing in the Genomic Medicine
Center a decade ago. We are even
more fortunate that the hospital
has supported it strongly ever
since. The Genomic Medicine
Center is a world-wide leader
in genomic medicine and has
received international recognition
for providing whole genome
sequencing and clinically relevant
results for critically ill infants, all

within a few days. The Genomic
Medicine Center is now bringing
genomic medicine to every cancer
patient at Children’s Mercy, both
clinically and through its research
initiatives via the Tumor Bank and
the Children’s Mercy Research
Institute Biorepository.
By utilizing the Genomic Medicine
Center’s existing infrastructure, we
are easily able to perform whole
genome sequencing for pediatric
cancer patients in-house. For such

Making this distinction is critically important
since: 1) tumor-specific genetic changes can be
used to match tumors to precision therapies that
attack only cancer cells and spare healthy cells
(unlike traditional chemotherapy which affects
both cell types) and 2) inherited changes that
confer predisposition to cancer are necessary
to examine in the pediatric setting because
these mutations are found in 5-15% of children
with disease, much higher than what was
previously believed.
Finally, in-house sequencing allows us to
have much more control over the quality
of sequence data that is generated. This
is essential for clinical sequencing where
strict quality control and validity of results is
the highest priority. In-house sequencing
also supports local researchers because
they can drop by, ask questions, and
see the process first hand. In turn, this
fosters additional stronger research
collaborations. Overall, in the end, doing
local sequencing brings us closer to
the goal of precision medicine: “finding
the right drug for the right patient at
the right time,” as informed by genetic
results.

IDENTIFYING THE DIFFERENCES
IN CANCER CELLS
Other than identical twins, all individuals have a unique
genetic makeup. This is due to certain sequence differences in
their DNA, specific to them, that are carried by all of their body’s
cells. Cancer cells, in addition to carrying all of the genetic
variants seen in normal cells, have additional genetic changes
that differentiate them from normal cells and which help define
such cells as cancerous.
In clinical cancer sequencing, it is critical to distinguish genetic
variants carried only by cancer cells (“somatic” changes) versus
those carried by all cells (“germline” changes) because somatic
changes can help guide precision therapy. In other words, this
information can help find a drug or agent that specifically targets
the genetic differences found in cancer cells, and ultimately does
not affect normal cells.

Most clinical cancer sequencing assays looking for these changes
in a cancer’s genetic makeup test only the tumor sample, making
it difficult to differentiate “somatic” changes from “germline” ones.
We recently questioned how many genetic variants found by clinical
cancer sequencing tests done at outside laboratories for pediatric
cancer patients that had been seen at Children’s Mercy actually found
changes that were truly tumor-specific (somatic) versus in all cells
(germline).
We did this by resequencing both tissue from the patient’s tumor, along
with normal cells found in the same patient’s peripheral blood. We found
that only 11 of the 41 variants (27%) found by outside laboratories were
actually somatic, which would imply that only certain therapies would
truly be precise and specifically target tumor cells. This study’s importance
was recognized when it was one of a few selected to be presented as
a poster and as a talk at a large international scientific meeting held in
Washington, D.C. by the Association for Molecular Pathology.
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Erin Guest, MD
Midhat Farooqi, MD, PhD

CANCER GENOMICS

RESEARCH
LEUKEMIA/LYMPHOMA
Acute lymphoblastic leukemia in
infants
Sadly, only about one in three
infants less than 1 year of age
with acute lymphoblastic leukemia
(ALL) survives despite intensive
therapy. Erin Guest, MD, is
leading an international clinical
trial with the Children’s Oncology
14

Group (COG) to test the safety of
the addition of azacitidine, an
epigenetic demethylating agent, to
chemotherapy for infants with ALL.
Blood and bone marrow samples
from infants enrolled in this trial
and in a prior COG trial for infants
with ALL are being studied in
the Genomic Medicine Center at
Children’s Mercy. In collaboration

with researchers at Johns Hopkins
University, we are performing
in-depth sequencing analyses to
discover biomarkers that better
predict response to treatment and
to determine the biological basis of
resistance to chemotherapy after
relapse. We presented our early
findings in abstract form at the
annual meeting of the American
Society of Hematology.

Measuring response to epigenetic
treatment
Epigenetic medicines are designed
to alter the expression of genes
by turning them off or on, thereby
leading to cancer cell death and/
or vulnerability to chemotherapy.
The Children’s Mercy Cancer Center
partnered with the Therapeutic
Advances in Childhood Leukemia
& Lymphoma consortium to

study samples from patients
enrolled in a trial for treatment
of relapsed leukemia. Samples
were sequenced to determine
the pharmacodynamic changes
in DNA methylation and histone
acetylation. The results show
evidence of potent anti-leukemia
effects by the epigenetic drugs.
This work has been submitted for
publication in conjunction with the
overall trial results.

Single-cell sequencing in infantile
and T-cell acute lymphoblastic
leukemia/lymphoma
Not all cancer cells are alike.
One patient’s cancer can contain
multiple distinct sub-clones. This
makes cancer difficult to target
with a single approach because
some sub-clones may be resistant
to certain therapies. At Children’s
Mercy, we are utilizing powerful
15

sequencing strategies that analyze
individual cancer cells for changes
in gene expression. We are taking
this innovative approach with all of
our patients with newly diagnosed
or relapsed leukemia, and we are
particularly focused on
determining the subclones that explain
resistance to treatment
in infant ALL and
childhood T-cell ALL,
because both of these
cancers are extremely
difficult to cure after
relapse.

therapy responses and outcomes.
This project aims to reveal novel
genomic changes in these tumors,
as well as novel associations
between genetic alterations and
specific clinical findings.

CENTRAL
NERVOUS
SYSTEM
TUMORS
Genomics of highgrade gliomas of the
brain
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SOLID TUMORS
Genetic and epigenetic targets for
treatment in solid tumors
Children with solid tumors that do
not respond to standard therapy or
relapse despite standard therapy,
have a very poor prognosis. This is
largely due to the limited number
of treatment options available. This
project supports a national clinical
trial where children with relapsed/
refractory solid tumors, including
neuroblastoma, osteosarcoma
and Wilms tumor, among others,
are treated with a novel immune
therapy that works to help control
disease. Unfortunately, not all
patients respond to this treatment.

Exosomes in Ewing sarcoma
Exosomes are tiny particles that
are released by tumor cells,
which contain components of the
original cancerous cell. Because
they can be found in blood, the
hope is that exosomes can be
used to monitor tumor burden and
serve as a valuable biomarker
for disease. This study has found
that exosomes produced by Ewing
sarcoma cells are detectable in the
blood of patients with disease. It is
currently working to develop this
finding into a clinically-available

blood test that would be used
to detect the presence of Ewing
sarcoma cells earlier than an MRI
or other radiology scans.

that can help explain disease
biology and also be specifically tied
to relevant clinical findings.

Rhabdomyosarcoma

ETHNICITY AND
GENOMICS

Rhabdomyosarcoma is the most
common type of soft tissue
sarcoma found in children with
about 400 to 500 new cases
occurring in the United States
each year. More than half
of rhabdomyosarcomas are
diagnosed in children younger
than 10 years old. What causes
these tumors to arise is not
clearly known. This study is
looking for pathological changes,
chromosomal abnormalities,
expression differences and genetic
sequence alterations in these
tumors, correlating them to specific
patient characteristics, therapy
responses and outcomes. The goal
of this project is to reveal novel
genomic features in these tumors

Hispanic and Native American
children diagnosed with Acute
Lymphoblastic Leukemia (ALL)
in the United States have the
poorest outcome when compared
to whites, Asians and AfricanAmericans. Some studies have
demonstrated that the higher the
percentage of Native American
(Pre-Columbian) ancestry among
children with ALL portends worse
overall and event-free survival as
well as a less favorable response
to end of induction therapy. The
term Hispanic, as it is used in the
United States, is very broad and
is not specific or descriptive of
actual ethnic and racial admixture.
The term does not account for
individual ancestry such as

Mexican, Guatemalan, Peruvian,
Puerto Rican ancestry or the
various combinations of ancestry.
As a result, knowledge regarding
which Hispanic groups have the
worse outcome remains unknown.
The term Hispanic as used in the
United States does not account
for the vast diversity of European
and Pre-Columbian ancestry. The
vast majority of the population is
an admixture of European and
Native indigenous populations
(Pre-Columbian ancestry) which is
referred to as the Mestizo. Mestizo
genetic ancestry is associated with
a higher incidence and poorer
outcome of ALL. Analyzing ethnic
profiles of children diagnosed with
ALL may be crucial to improving
outcome among Hispanics in
Mexico and the United States.
Terrie Flatt, DO, along with
collaborating institutions in
Mexico, is conducting research
studies to look into genetic links
between ethnicity and how
children respond to treatment.
By partnering with international
hospitals, Dr. Flatt has
established both research and
clinical links that provide benefit
to all.
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Brain tumors are the most
common solid tumor in children,
as well as the most common
cause of solid tumor-related
deaths in childhood. Why they
arise and what predisposes
them to be “high-grade” and
aggressive versus “low-grade”
and more benign in nature is
not completely understood.
This study is comprehensively
analyzing genomic changes found
in high-grade glial brain tumors,
such as copy number changes,
chromosomal abnormalities,
expression differences and
genetic sequence alterations,
and correlating such findings to
specific patient characteristics,

This study aims to comprehensively
profile the genomes of tumors
being studied by the clinical trial,
both before and after immune
therapy, to look for specific
genetic markers that correlate
with therapeutic
response. The
project has a
special emphasis
on detecting certain
chemical changes
to DNA (epigenetic
modifications)
that are known to
play a key role in
tumor response
to immune-based
cellular therapies.
Overall, the study’s
goal is to use
genetic information
to guide and
support use of a
novel targeted therapy for pediatric
patients with relapsed/refractory
solid tumors.
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Teenagers are famous for burning the candle at both ends, and Teo
Rosales was no exception to that rule. In May 2018, he was busy with
his classwork and involved in the school’s robotics team, a typical
sophomore at Olathe Northwest High School.
But one Monday morning before school, he had a nosebleed—a
nosebleed that lasted for almost two hours. Later that week, his
mother, Amee, began noticing that when her son got home from
school, he would sleep all afternoon, eat dinner, then go back to sleep
again. He also was experiencing lots of bruising.
So when Teo’s father, Ruben, took him to the pediatrician, he was
referred immediately to the Children’s Mercy Emergency Department.

TARGETING

TEO’S
CANCER
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After performing a series of
blood tests, doctors delivered
some devastating news to Teo
and his parents. He had a rare
form of leukemia called acute
promyelocytic leukemia, a cancer
of the blood-forming tissue, or
bone marrow.
“When I first heard the news, I
froze. My entire world stopped,”
Teo said. “I looked over at my
parents, and there was a moment
of silence.”

products in the first seven days
he was hospitalized to reduce his
white blood cell count and stabilize
his blood’s ability to clot.
Working with Dr. Guest on Teo’s
case was Oluwaseun “Kemi”
Olaiya, MD, pediatric hematology/
oncology fellow.

Teo was admitted to the hospital
that night and treatment began
immediately.

“The type of cancer Teo had
has a very specific molecular
rearrangement that we can test
for and target with treatment,”
she explained. The Children’s
Mercy Genomic Medicine Center
performed the initial testing
that determined the molecular
rearrangement for Teo’s cancer.

“We knew from Teo’s blood work
that he was at extremely high
risk for internal bleeding,” said
Erin Guest, MD, Director of the
Cancer Genomics Program and the
Cancer Center Biorepository. Teo
received 6 units of blood in the first
24 hours, and 36 units of blood

Thanks to that information, Teo
qualified for a special Children’s
Oncology Group phase III trial for
patients with newly diagnosed
APML, study number AAML1331.
Children’s Mercy is the primary
pediatric cancer provider and the
only NCI Children’s Oncology Group

TEO’S TREATMENT
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institution in the Midwest Cancer
Alliance.
“This is a very targeted approach
for this type of leukemia,” Dr. Guest
said. “We have been learning a
lot more about genetics and the
genes that are in each type of
cancer. Those are really important
markers for how easy or difficult it
will be to treat the patient’s cancer,
and in Teo’s case, it guided us
toward this study protocol.”
Teo also was fortunate he was
referred to a pediatric hospital for
his care versus an adult hospital.
“Not only do we have access to
these COG protocols, but research
has shown that adolescents have
better outcomes when treated in
a pediatric hospital, and benefit
from all the resources and
services we have to offer, like
child life, pediatric subspecialists,
pharmacists, nutritionists and
social work
support,” Dr.
Guest said.

A UNIQUE STUDY FOR A
UNIQUE CANCER
Though chemotherapy is the
traditional treatment for APML, this
study took a different approach.

Throughout his therapy and followup, data about Teo’s response to
treatment has been submitted to
the COG study investigators as part
of the protocol.

“Teo did have a small amount of
chemotherapy initially,” Dr. Guest
explained. “But the primary drug
used in this trial was arsenic, plus
all-trans retinoic acid (ATRA).”
Arsenic is a poison, but it also
can be an effective treatment
for cancer, and it doesn’t cause
the typical side or late effects
associated with traditional
chemotherapy. The arsenic was
delivered via IV, and ATRA via an
oral pill.
“It kind of weirded me out that the
arsenic was in my body,” Teo said.
But he responded quickly to the
therapy and went into remission.
While in the hospital, Teo passed
the time gaming online with his
brother, and visiting with friends
who delivered lots of fast food to
him.
“It’s important to still continue
with your life as normal as you
can, even when the crazy
stuff is happening,” he
said.
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Today, Teo is doing great. He visits
Drs. Olaiya and Guest every three
months to monitor his blood for the
gene rearrangement. So far there
are no signs of relapse.

Teo marked his 17th birthday
at Children’s Mercy, and even got
to meet several of the celebrities
who were in town for the Big Slick
fundraising event in 2018.
“I talked with Charlie Day from It’s
Always Sunny in Philadelphia, Paul
Rudd from Antman, and Angela
Kinsey from the Office, ” he said.
“It was great to talk with Angela
because my friends and I are into
the Office.”

HOME AT LAST
After spending 28 days on the
Children’s Mercy Oncology Unit,
Teo was released to go home.
He continued treatment in the
outpatient Oncology Clinic, having
three-hour infusions Monday
through Friday for a month, then
taking a month-long break,
followed by another month on
treatment and another month-long
break. That cycle repeated until the
full COG protocol was finished in
January 2019.

“Teo responded great to the
trial,” Dr. Guest said. “His biggest
challenge was actually a fear of
needles, which are a necessary
part of treatment.” The Children’s
Mercy Child Life specialists helped
him deal with that fear, and
successfully complete treatment.
“The day my treatments ended
was a very emotional moment for
me,” Teo said. “I did it! It was like
a weight had been lifted off my
chest. I don’t have to worry about
the cancer anymore.”

“The investigators are looking for
a treatment that may be better
than the standard treatment,” Dr.
Olaiya said. “We were excited
about the clinical trial and how
Teo responded. These aren’t new
drugs, but they hadn’t necessarily
been used in this combination
and without further traditional
chemotherapy to treat this type
of cancer before. Our hope is that
this research will help change the
standard of care for other children
diagnosed with APML.”

LOOKING TO THE FUTURE
As he completes his senior year of
high school, Teo readily admits this
experience has changed his life.
“I don’t take anything for granted,”
he said. “I really appreciate waking
up to a beautiful Kansas sunrise
and admiring the beauty of the
earth.”
He looks forward to tomorrow, and
has been accepted at Kansas State
University where he plans to major
in anthropology.
“I have been given a second
chance at life,” Teo added. “I want
to be able to do something that I
love, that can make other people
appreciate the world and the
people in it, and that can create a
more sustainable future.”

“Everyone at Children’s Mercy was
wonderful,” Teo’s mom said. “The
nurses, social workers and doctors
were very good to us. Teo is really
needle-phobic so it took a lot to
get him infused and used to the
needles, but his psychologist and
child life helped with that.”
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FLOW LAB
The Flow Cytometry Lab is a specialty testing area of the
Department of Pathology and Laboratory Medicine. It is
a supportive and diagnostic methodology that provides
basic and specialty analyses to the physician in making
patient diagnoses and prognoses.
Flow cytometry testing allows for comprehensive
investigation of cells within a specimen. Our test menu
includes leukemia/lymphoma immunophenotyping,
DNA ploidy, lymphocyte subsets including naïve and
memory T/B cells and recent thymic emigrants, ALPS
screening and CGD screening.

MOLECULAR GENETICS LAB
The Molecular Genetics Lab is a specialty testing area of the Department of Pathology and Laboratory Medicine that
assesses samples from patients diagnosed with cancerous and non-cancerous conditions to look for specific genetic
differences via traditional molecular techniques. In doing so, the Molecular Genetics Lab compliments the Genomic
Medicine Center by offering a wide variety of additional methodologies to look for these genetic changes, including DNA
amplification, fragment analysis and sequencing. The lab can also perform testing on a range of sample types such
as blood and bone marrow specimens, buccal swabs, fresh tissue and tissue that has been fixed in formalin, allowing
testing to be done on a wide variety of cases and for nearly all patients.

CANCER CYTOGENETICS PROGRAM
The Children’s Mercy Clinical Cytogenetic Laboratory performs genetic analysis of tumor samples from all children with
new diagnoses of leukemia, lymphoma or a solid tumor. Study of tumor cells at diagnosis reveals genetic changes that
define the tumor type and subdivide tumors into genetic subgroups. This information is used to personalize care and
determine optimal therapeutic protocols for that child’s specific tumor. The genetic information is especially critical for
stratifying patients enrolled in Children’s Oncology Group (COG) protocols for the treatment of new diagnosis leukemias.
Solid tumor genetic analysis facilitates pathological diagnosis and subtyping, selection of therapy, and predicting outcome.
The laboratory utilizes gold standard methods, such as chromosome analysis and fluorescence in situ hybridization, as
well as front-line technologies such as microarray and somatic mutation analysis.
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One of our important tasks is classifying childhood
leukemias and lymphomas. The testing panels
contain antibodies specific for T-cells, B-cells,
monocytic, myeloid, blasts and other cell types.
Additionally, we have developed leukemiaspecific minimal residual disease (MRD) panels
for monitoring after therapy. These panels can
identify very small numbers of leukemia cells
that may be present. Our lab is the only one in
Kansas that is approved to perform COG testing
panels for B-ALL MRD. DNA cell cycle and ploidy
measurements are useful to exhibit abnormal
genetic material content. Besides providing
leukemia lineage classification and DNA ploidy,
our lab is developing an assay for CRLF2
expression. A high level of CRLF2 expression
is seen in BCR-ABL1-like B lymphoblastic
leukemia/lymphoma, which can benefit from
treatment with tyrosine kinase inhibitors.
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GENETICS AND 						
GENETIC COUNSELING
In some cases, pediatric cancers
are associated with inherited
mutations in cancer-causing
genes. There are several genes
that are known to increase the risk
of cancer in children. Children with
a strong family history of cancer
or a cancer type that is associated
with a known cancer syndrome
can especially benefit from genetic
counseling.

a sarcoma should be evaluated
for the possibility of Li Fraumeni
syndrome, which can cause
sarcomas, along with a wide
variety of other cancers both in
childhood and adulthood. If a
hereditary cancer syndrome is
identified, at-risk relatives including
parents, siblings and extended
family members, can be tested for
the familial mutation.

Genetic counselors are trained to
elicit a detailed multi-generation
family history and perform a risk
assessment, as well as explain
the benefits, limitations and
implications of genetic testing
to both medical providers and
families. For example, a child with

Individuals with hereditary cancer
syndromes frequently need
increased lifelong surveillance that
is tailored to their particular cancer
risks. Genetic testing can identify
which individuals in a family need
increased surveillance, which may
be lifesaving. The Children’s Mercy

Caitlin Schwager, MS, CGC

CLINICAL
RESEARCH

Division of Clinical Genetics has a
genetic counselor who specializes
in evaluating for pediatric
hereditary cancer syndromes and
is regularly involved with families
in which hereditary cancer is
suspected.
We also have a Surveillance for
Predisposition to Tumors (SPoT)
Clinic that is designed to follow
children who have tested positive
for a hereditary cancer syndrome
and need individualized tumor
surveillance. For more information
about genetic counseling and
genetic testing for pediatric oncology
patients, contact Genetic Counselor
Caitlin Schwager, MS, CGC, or the
Division of Clinical Genetics.

CHILDREN’S MERCY
RESEARCH INSTITUTE
The Children’s Mercy Research Institute is creating an integrated
research environment where no boundaries exist between science
and medicine. In our quest to find answers to pediatric medicine’s
most challenging questions, we are collaborating with physicians,
scientists, academic colleagues, philanthropic partners and others
within our community, and around the world.
To accomplish our goals, we’re performing the highest quality
research using the latest medical technologies. The hospital’s
leadership in pediatric genomic medicine and clinical
pharmacology is driving research and innovation in nephrology,
heart care, cancer treatment and other subspecialties to provide
answers for the most difficult cases and challenging pediatric
conditions.
Integral to our efforts is our focus on applied informatics, the use
of cutting-edge computational capabilities. Informatics helps us
provide answers to children and their families by accelerating the
process of research, improving the quality of research, making it
possible to share data with other researchers, and even making
new methods of research available.
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In 1948, Sidney Farber published results
of a new treatment for children with
leukemia. Farber’s article was one of
the first that showed promise for any
possible therapy for a disease that killed
every child diagnosed. Today, the cure
rate for childhood acute lymphoblastic
leukemia is around 90%. Since Farber’s
article, it has been clinical research trials
and the willingness of parents to enroll
their children on these trials that has made
this remarkable progress.
For decades, Children’s Mercy has been an
active member of the international pediatric
cooperative groups funded by the National
Cancer Institute. Every child diagnosed
with cancer is treated on a clinical trial, or
is treated according to the most up-to-date
standard therapy vetted by research.
As cure rates have risen, the focus of the
research and new therapies have changed.
We now look into the elements of the disease
that may only be seen at the genetic level.
Several of the studies that Children’s Mercy
participates in have biological components
that seek answers to questions about what
triggers disease and response. A team of clinical
research professionals work with Children’s
Mercy physician researchers to bring research
studies to our families. They work behind the
scenes to prepare study documents, seek the
necessary regulatory approvals, collect data,
and collect biology specimens. With the growth
of the Cancer Genome program, the scope of
our research will continue to evolve to include the
capabilities of this expertise.
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FaCT

referrals to assist with financial
concerns, transportation and
lodging needs, support and mental
health referrals. Every patient
has an assigned clinical social
worker who follows the patient
and family through diagnosis,
treatment, relapse, survivorship or
bereavement.

Multidisciplinary care is integral to the overall outcomes and well-being of our patients. Outside of medically
directed care, patients and families have many other needs that are addressed by our Family Care Team
(FaCT). Regular FaCT rounds and collaboration ensures that all the physical, developmental, emotional,
educational and spiritual needs are met for our patients and families. The Family Care Team is available to
assist from point of diagnosis through the completion of treatment and beyond for patients with cancer.
The Patient and Family Support
team consists of child life
specialists, a school teacher, music
therapy, and a patient activity
assistant, who is also the handler
of the facility dog on staff working
on the inpatient unit. Together,
the team works collaboratively
to support the psychosocial and
developmental needs of children
and families.
Child life specialists are
trained professionals who
help children cope with the
stress and uncertainty of illness
and hospitalization. Child life
specialists are child development
experts who work to ensure life
remains as normal as possible
for children in health care settings
through preparation, coping and
normalization. Preparation is
provided by child life specialists
who explain and teach patients
about medical procedures, coping
skills and other health care
experiences. Coping facilitation
promotes effective coping
strategies to help reduce anxiety
and enhance cooperation with the
health care event or diagnosis.
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As advocates of family-centered
care, child life specialists work in
partnership with the medical team
to meet the unique emotional,
developmental and cultural needs
of each child.
Hospital-based school teachers
establish a positive learning
climate of success for students
with chronic and serious medical
conditions, and coordinate
educational plans with the patient’s
home school.
Music therapists provide
opportunities for self-expression
and development of positive
coping skills to promote increased
comfort, and to support

developmental growth. Music
interventions are designed after an
assessment of need and generally
involve the use of both live vocal
and instrumental music, as well as
technology. Goals may include, but
are not limited to the reduction of
pain or anxiety; increased selfexpression and positive changes in
mood; increased physical strength
and endurance; greater relaxation;
learning positive coping strategies;
and the support of developmental
skills. Patients are encouraged to
take an active role in making music
and learning how to use music as
a helpful and fun tool.

Patient activity coordinators
provide patient and family activities
and volunteer supervision.

Clinical social workers are
master’s-level licensed
professionals working as part
of the primary team to provide
comprehensive and compassionate
family-centered care. Social
workers understand that any
change in the child’s health can
alter a family’s life in many ways
and are trained to provide a
thorough assessment and address
the ongoing needs of the patients
and families. Social workers can
help with therapeutic support,
including adjustment to illness,
crisis intervention, development
of coping skills, family concerns,
end of life, and bereavement;
care planning including education
on advance directives, school
concerns, legal issues, transition
to adult care, and end-of-life
concerns; and community/resource

The Parent-to-Parent Program
(PTP) continues to offer support
and comfort to all of the families
within our division through the
use of specially trained parent
volunteers and a clinical social
worker dedicated specifically to
PTP program management. There
are many services offered through
the PTP program, including parent
volunteers available to share, listen
and support our current parents/
caregivers; two stocked parent
rooms that offer weekly dinners,
breakfasts, therapeutic and
educational activities and a safe

place to unwind while a child is an
inpatient; “care bags” for families
upon unexpected admissions
to help ease some burden of a
hospital stay; and new parent
journals.
The Parent-to-Parent program also
offers an extensive bereavement
follow-up program that supports
families for approximately 13
months after a child’s death. We
have successfully introduced
social media into our bereavement
follow-up program and have been
able to offer additional support.
PTP has worked closely with a
number of local organizations, as
well as the Children’s Mercy Cancer
Center, and has established
ongoing philanthropic support
of the parent rooms to serve the
increasing needs of our inpatient
families. The Parent-to-Parent
Program has been innovative
in establishing this program
model and was highlighted at the
Association of Pediatric Oncology
Social Workers conference in 2017.
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The Adolescent and Young Adult (AYA) program is designed
to support patients receiving treatment for cancer or blood
disorders. The team of providers includes a clinical social worker
and child life specialist who work in collaboration with other
disciplines toward the goal of improving the quality of care
for the AYA population. Recent accomplishments include the
development of a teen unit and teen room on our inpatient floor;
a formalized peer mentoring program; additional programming
and education around fertility preservation; and improvements
to the process around transitioning to adult care. Ongoing
projects include the Hematology/Oncology Teen Advisory
Board; Teenapalooza events to promote peer interaction; and
ongoing education and support.
There are two dedicated psychologists to assist patients and
families with coping with the diagnosis and treatment of
cancer. They are available to meet with patients and their
families, both while hospitalized and when outpatients. In
addition to clinical therapeutic services, the psychologists
are also able to complete neuropsychological evaluations
to assess any impact of medical treatment on brain
functioning, and to assist with school re-integration and
planning.
As a member of the Hematology/Oncology/BMT team,
the chaplain regularly provides spiritual and emotional
support to patients and families during the course of a
child’s illness, as end-of-life discussions are necessary,
at the time of death, and beyond. Providing tailor-made
rituals for patients and families at the time of significant
events, like bone marrow transplant, is another way a
chaplain provides support. At the request of the family,
the chaplain can contact a family’s own clergy person/
spiritual leader. For families who live outside the
Kansas City area, again at the request of the family, the
chaplain contacts a local leader from the family’s faith
tradition to provide additional support. The chaplain
provides education about the spiritual resources that
are available within the hospital, such as Sunday
worship, concerts and celebrations from various
faith traditions, and other activities in the Lisa Barth
Chapel. The chaplain participates in team meetings.
Providing support to the staff is another important
role of the chaplain.
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The Black & Veatch Building, on the Children’s Mercy Adele
Hall Campus in Kansas City, Mo., houses the Division of
Hematology/Oncology/Blood and Marrow Transplant.
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Wearing glittery pink sneakers and hugging a fluffy pink and white
leopard print blanket, when 2-year-old Clara Jensen looks at you
with those big brown eyes, all you see is an adorable, happy, healthy
toddler. But that’s not how life started for this child.
A full-term infant, Clara’s parents
and doctors were caught
completely off guard when
she was born Sept. 21, 2017 at
AdventHealth (formerly Shawnee
Mission Medical Center). That’s
because she had a tumor on the
back of her tongue—a tumor the
size of a golf ball. In fact, it was
so large Clara couldn’t close her
mouth, or eat.

“It’s not routine at most hospitals,
but we’re actually able to offer
every patient who comes to
Children’s Mercy molecular and
genetic testing that may allow us
to change their treatment,” said
Erin Guest, MD, Director of the
Cancer Genomics Program and the
Cancer Center Biorepository. That
additional step turned out to be
critical in Clara’s case.

Immediately, doctors transferred
Clara to the Neonatal Intensive
Care Unit at Children’s Mercy for a
higher level of care. Initially, no one
was sure what the growth was, but
doctors placed a gastrostomy, or
G-tube for feeding. As an added
precaution, they also placed a
tracheostomy, or breathing tube,
in case the growth became larger
and blocked Clara’s airway.

RARE DIAGNOSIS

Once those were in place, Clara
had an MRI, plus a surgical
procedure to collect tissue for a
biopsy, and to reduce the size of
her tongue.
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CLARA’S
CLINICAL TRIAL

Based on preliminary test results,
doctors determined the growth on
Clara’s tongue was a malignant
tumor. They weren’t sure of the
exact tumor type though, so they
sent the biopsy for more extensive
testing.

About three weeks after the biopsy
was performed, Aaron and Jennifer
learned their baby had a rare form
of cancer called an inflammatory
myofibroblastic tumor.
“It was a bit of a shock when the
doctors told us Clara’s diagnosis,”
Aaron said. And the traditional
treatment was more than a little
scary for this Independence family.
“The doctors said usually with
this type of tumor, they remove
it surgically, but because Clara’s
tumor was on her tongue, no one
wanted to do that,” Jennifer said.
“Clara’s tumor was extremely rare,”
Dr. Guest said. “But with the results
of the molecular testing, we were
able to identify an abnormality in
the ALK gene, which is present
in about half of these types of
tumors,” she explained.
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Crizotinib is approved to treat
adults with advanced stage
lung cancer whose tumors are
ALK-positive. It’s not a form of
chemotherapy, and it has very
few side effects.
But the drug had never been used
to treat the type of tumor Clara
had, and because she couldn’t
swallow, Clara needed a liquid
form of the medication so that she
could receive it via her G-tube.

COMPASSIONATE USE
Inspired by this tiny girl with the big
brown eyes, the oncology team not
only found a liquid form of the drug
in development, they applied for a
compassionate use trial.

Those findings led Clara’s oncology
team to search for a drug called an
ALK inhibitor. Though they found
a medication they thought would
work, it wasn’t FDA-approved or
commercially available to treat the
type of tumor Clara had.
“Crizotinib is a molecularly targeted
drug that stops cells from growing.
The tumor was dependent on that
ALK gene rearrangement to grow,
and if we could halt that, it would
give the tumor an opportunity to
shrink,” Dr. Guest said.
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“A compassionate use trial is
basically something we can apply
for when there are no other good
treatment options available for
a patient,” Dr. Guest explained.
Though securing approval for this
type of trial can take weeks, the
Children’s Mercy oncology team
received approval in days.

“This was basically a clinical trial
just for Clara,” Dr. Guest explained.
Before the Jensens knew it, Clara
was receiving the life-saving
medicine via her G-tube, and the
tumor began to shrink.
“Our other children were sick
about the same time Clara started
receiving the medication, so I
couldn’t go see her for a week,”
Jennifer said. “When I went back to
the hospital, I said, ‘Wow! Look at
her tongue!”
Clara’s tongue was visibly shrinking,
and it continued to shrink until the
tumor was completely gone.
In all, Clara spent 80 days in the
Children’s Mercy NICU being
closely monitored for any side
effects to the medication.
“Other than some mild nausea,
Clara didn’t experience any side
effects,” Aaron said.

When the Jensens took her home,
they continued the medication,
giving it as prescribed, twice a day
for an entire year.

COMPLETE REMISSION
“Clara has had a complete
remission of the tumor,” Dr. Guest
said. “She’s not had to have any
further surgeries or radiation or
chemotherapy. Just that single
medicine was enough to get rid of
the rest of the tumor.”

would go to the hospital, watch her
struggle and feel helpless.”
But those days are long gone. Now
2 years old, Clara sees Dr. Guest
every three months for follow-up in
the outpatient oncology clinic. Her
most recent MRI was all clear.

speech development, amazingly, it
hasn’t. “Clara is very articulate for
a 2-year-old,” Aaron said.
“We’re so grateful for everything
that Children’s Mercy has done
for us and other cancer patients,”
Jennifer added. “We’ll never forget
how dedicated they were.”

And even though the tumor could
have affected her tongue and

Plus, Clara no longer needs a
tracheostomy or G-tube, and
because this medication isn’t a
chemotherapy drug, she won’t have
to face the late effects of treatment
many cancer patients do.
“We had so much anxiety and
stress when Clara was sick,”
Jennifer said. “There were days we
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THE IMPORTANCE OF

BIOINFORMATICS
AND DATA SHARING

tools they need to sort through this
data and find the information they
need to tailor the treatment to the
individual child,” Miller said.
The center also is working on
pharmacogenomic testing that
looks at the patient’s genes and
helps clinicians determine which
medications will generate the best
clinical response.

IN PEDIATRIC CANCER DIAGNOSIS
AND TREATMENT

In a tiny room deep inside the Genomic Medicine Center at Children’s Mercy Kansas City is one of the most
powerful pieces of technology there is in the fight against pediatric cancer—a super-computer that’s home
to 3 petabytes of genetic data!
To give you an idea of just how
much data that is, it would take
1.5 million CD-ROM discs to store
one petabyte of data. The center
has three times that! To think
of it another way, the supercomputer has more than 2,300
compute cores – the equivalent
of more than 500 normal desktop
computers.

Center. “The take-home story is
that genomic data are very big,
and it takes a lot of horsepower to
drive this technology.”

To keep that super-computer
humming along, the center
has 8 tons of air conditioning,
conditioned power and hospital
emergency back-up power.

“By providing sequencing for our
patients right here, we can turn
results around quickly,” Miller
said. “Plus, we have a very skilled
and knowledgeable team focused
on delivering the highest quality
results for our patients, and giving
clinicians the best possible insights
into the conditions they treat.”

“This computer does much of the
heavy computational lifting for
us,” said Neil Miller, Director of
Bioinformatics, Genomic Medicine
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Children’s Mercy is one of the few
hospitals in the nation dedicated
to generating its own genomic
sequencing data and performing
all analysis on site.

Cancer is just one of the many
diseases and conditions this supercomputer helps diagnose and treat.
“The vision is to be able to provide
detailed molecular profiling for
every patient,” Miller said. “By
identifying the mutations in the
patient’s cancer, our doctors can
better personalize and target their
treatment.”
To do that, the center also utilizes
a variety of software tools that
characterize the genetic information
that’s relevant to the clinician.
“This technology generates a
tremendous amount of information,”
Miller said. “In the end, what we
try to do is give the oncologist the

And, to assist with cancer research, the
center is performing retrospective tumor
bank sequencing, and working to share
this data with researchers outside Children’s
Mercy.
“Our goal is that by sharing this database
with the broader scientific community,
researchers will be able to find patients with
the same genetic mutations, and they can use
that information to better inform treatment or
develop research protocols,” Miller said.
Plus, patients and families can bank their tumor
information for use in future research that may
one day help other children facing a cancer
diagnosis.
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SEARCHING FOR

GENOMIC ANSWERS
When a child is diagnosed with cancer, the question “Why?” becomes more relevant than ever. Patients,
parents, clinicians and researchers all want to know the answer to that one question. Often, there is no
answer, but thanks to the Children’s Mercy Genomic Medicine Center, that may one day change.
Established in 2011, the center
was the first of its kind with a
pediatric focus and has become an
epicenter for genomic research at
Children’s Mercy, and around the
world. Led by Tomi Pastinen, MD,
PhD, Director, the center’s focus is
to increase the diagnosis rate for
rare diseases in pediatric medicine.
“Currently, less than half of kids
with rare diseases get an answer
from molecular testing,” Dr.
Pastinen said. “We want to change
that—we want the majority of
kids to receive an answer from a
molecular test, including children
diagnosed with cancer.”

“This technology allows us
to look at the ‘blind spots’ in
current diagnostic sequencing
technologies,” Dr. Pastinen
explained. “This is achieved
by generating much longer
sequencing reads than
conventional technologies can. We
believe that this unexplored space
may hold some of the answers we
are looking for.”

Tom Pastinen, MD, PhD

A flagship initiative of the
Children’s Mercy Research Institute
and the center is an initiative
called Genomic Answers for Kids.
This initiative is in the early stages
of collecting and storing genomic
information and biological samples
from children and their biological
family members who have a rare
genetic condition. The resulting
database will be a rich resource
for researchers studying genetic
conditions, potentially leading to
answers and new treatments for
children.

“We envision that rare forms of
pediatric cancer have a heritable
basis in up to 10 to 20 percent
of cases,” Dr. Pastinen said. By
systematically employing the
center’s advanced set of genomic
tools, he believes they will uncover
more inherited mutations in these
patients.
This information could help
potentially identify the molecular
switch responsible for the cancer.

Armed with that information,
clinicians would be able to search
for treatments targeted at specific
genetic mutations.
While Dr. Pastinen admits this will
be a long journey, he’s hopeful
Children’s Mercy can accelerate
the pace of discovery and advance
the field of genomic medicine by
sharing the center’s database with
the scientific community.

“We are working as fast as we
can to implement these novel
genomic tools for patients with
unsolved rare diseases,” Dr.
Pastinen said. “These families
can’t wait for answers. They
want to know why their child is
sick.”

SPE CIA L FOC US
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To reach that goal, the Genomic
Medicine Center is utilizing several
novel technologies, such as thirdgeneration sequencing and singlecell genomics.
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Bryce Munson remembers the very first time he had what he thought

THE
MUNSONS’
SAFETY NET

was a panic attack. Mom Erryn Westerhold does, too.
“I was in my 7th grade math class when I started having trouble
breathing, my chest hurt, I couldn’t focus and my vision was blurry,”
Bryce said.
Erryn took Bryce to the family’s pediatrician, who prescribed antianxiety medication. For a while, the panic attacks stopped, but over
the next three years, they became more and more frequent.
“On the surface, it looked like I had a really, really bad case of
anxiety,” Bryce said. But he didn’t.
Erryn and Bryce’s father, Jerald
Munson, started to question
whether something else might
be causing their son’s anxiety
attacks and uncontrollable spikes
in his blood pressure. Jerald’s
mother had had an inherited
disorder called von Hippel-Lindau
syndrome, or VHL.
VHL is characterized by the
formation of tumors and cysts
in different parts of the body.
These tumors may be cancerous
or noncancerous, and often first
appear during young adulthood.
Though Jerald’s mother had
passed away from VHL, he
had never shown any signs or
symptoms of the disorder.
“We knew in the backs of our
minds that it was possible Jerald
could have VHL and the boys could
have inherited it, but it had never
been an issue,” Erryn said. Until
Bryce’s anxiety attacks began.
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DIAGNOSING VHL
Erryn started researching VHL and
found people with the condition
commonly develop a type of tumor
called a pheochromocytoma.
These tumors occur in the adrenal
glands, which are located on
top of each kidney. Though
pheochromocytomas are usually
not cancerous, they can cause
headaches, panic attacks, excess
sweating and dangerously high
blood pressure—all symptoms
Bryce had.

Clayton Munson

After discussing Jerald’s family
history with their pediatrician,
he referred Bryce to an
endocrinologist at Children’s Mercy
for further testing. Jerald and Erryn
recall the day they got the call that
Bryce had a pheochromocytoma
on his right adrenal gland.
“It was terrifying, actually,” Erryn
said. “I was at work when the
phone rang and they said we
needed to get Bryce to Children’s

Michael Munson

Bryce Munson
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Mercy immediately. I told them, ‘I
get off work at 5:30 p.m., and I’ll
bring him up then,’ but they said
we needed to get him there NOW.”
Erryn and Jerald dropped what
they were doing, and rushed Bryce
to the hospital. There, doctors
removed the pheochromocytoma
and his right adrenal gland.
While hospitalized, Bryce said
specialists lined up outside his
door. “I felt like I had 30 doctors!”
he said.
“He was pretty popular,”
Jerald said. “Endocrinologists,
neurologists and oncologists—
Bryce had a team of specialists
taking care of him at Children’s
Mercy. That’s the kind of care this
condition requires.”
After a few days in the hospital, he
returned home to Warrensburg to
recover. “I had lots of medications
to regulate,” Bryce said. “And I
had to take my blood pressure like
100-million times a day.”

Mom said it wasn’t quite that
bad, but she kept a journal of his
blood pressure readings that she
still has today. “I would send the
readings to his endocrinologist
every day, and she would adjust
his medications accordingly,” Erryn
said.

The SPoT Clinic team includes
Caitlin, Kevin Ginn, MD, pediatric
neuro-oncologist, and Erin Guest,
MD, Director of the Cancer
Genomics Program and the Cancer
Center Biorepository. They conduct
the clinic eight times a year,
following approximately 30 to 40
patients.

A few months later, Bryce returned
to Children’s Mercy to have a
smaller pheochromocytoma
removed from his left adrenal
gland via a cryoablation procedure.
Since then, he’s been tumorfree. No treatment other than
medication has been necessary.

ON THE SPoT!
When Bryce tested positive for VHL,
it generated a whole new level
of concern that everyone in the
Munson family, except Erryn, could
have the disorder.
First, Jerald tested positive for VHL.
He discovered he also has several
non-cancerous tumors throughout
his body. He’s had one removed
from his kidney,
and his doctors
are watching
him closely.
Though the
odds were
50/50 that
Jerald had
passed VHL on
to Clayton, 14,
and Michael, 11,
they also tested
positive for VHL.
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“That can be a lot for families
and primary care providers to
manage, especially if there are
multiple children involved, like the
Munsons.”

So far, neither has shown any
symptoms of the disorder, but
to be certain the brothers stay
healthy, they’re now followed in the
Children’s Mercy Surveillance for
Predisposition to Tumors, or SPoT
Clinic.
The clinic was developed to follow
patients with a variety of hereditary
cancer syndromes that predispose
them to different types of tumors in
all parts of the body. At each clinic
visit, the team reviews national
screening guidelines specific to
the patient’s diagnosis, and makes
sure the patient is current on all
surveillance testing.
“We focus on kids who have
complex cancer risks, meaning
their risk for tumor development
requires more complex screening
schedules,” explained Caitlin
Schwager, MS, CGC, Genetic
Counselor for oncology and
Manager of the SPoT Clinic.

“The SPoT Clinic is like a safety
net for these patients and their
families,” Caitlin said. “We can
improve adherence by following
established protocols, reducing the
risk that something will be missed,
and improving the quality of life for
these families.”

WE’VE GOT YOUR BACK
Bryce, Clayton and Michael take
comfort in knowing the SPoT clinic
team is keeping a close eye on
their health, allowing them to focus
on what’s important to three active
guys.
“I’m a senior in high school now,”
Bryce said. “I’m taking college
courses and I’m thinking about
getting a business degree.”
Clayton is the family daredevil. He
loves doing tricks on his bike and
playing soccer. He’s broken several
bones, but so far hasn’t developed
any tumors related to VHL.

And Michael, known to his
brothers as Mikey, loves
playing football and taking
care of his pet rabbit, but has
no symptoms of VHL either.
All three are followed in the
SPoT Clinic annually. Their
next imaging and lab tests are
scheduled for March 2020.
“To be honest, we dread that
time of year,” Jerald admitted.
“We know there’s a risk there
could be something we might
have to deal with, but so far,
we’ve gotten good news.”
Still, the concern is always in
the backs of their minds.

“Children’s Mercy is a great
hospital,” Jerald said.

“If one of the boys has a headache
more than a couple of days in a
row, or they don’t feel good, we’re
concerned it might not just be a
headache, or a virus, it could be
more serious,” Erryn said.

Erryn is grateful their Warrensburg
home is only an hour away from
the hospital’s Adele Hall Campus,
and the SPoT Clinic.

Jerald agreed. “We worry that the
minor stuff could turn out to be
something major.”

“I feel very blessed we live this
close to Children’s Mercy, and a
team of specialists who know what
VHL is and how to treat it.”

COUNTING THEIR
BLESSINGS …
Though Erryn and
Jerald have had a lot
to deal with since
Bryce’s diagnosis,
they’re thankful they
discovered it when they
did, and that Children’s
Mercy was in their
corner.
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NEURO-ONCOLOGY
The Children’s Mercy Cancer Center Neuro-Oncology Program is a
multidisciplinary program led by Kevin Ginn, MD. The primary focus of the
program is to provide access to advanced cancer therapy and to improve
outcomes for children in the Kansas City region with brain and spinal cord
tumors. Central Nervous System tumors remain one of the leading causes
of cancer-related deaths and morbidity and these patients benefit from the
individualized care plans developed by multiple subspecialists available at
Children’s Mercy.
Here, we treat approximately 50 new patients a year and each patient is
discussed at our twice-monthly multidisciplinary tumor boards. These tumor
boards allow in-depth discussion of new or established patients, ensuring
thorough care planning to improve patient care. Our involvement in national
consortiums such as Beat Childhood Cancer and the Children’s Oncology
Group (COG), as well as pharmaceutic industry relationships, allows us to
provide access to cutting-edge clinical trials for both new and relapsed
patients.
Research collaborations through the Midwest Cancer Alliance Partners and
the University of Kansas Cancer Center have resulted in funded research
investigating new therapies for glioblastoma and atypical teratoid rhabdoid
tumor, which are two of the most devastating tumors in pediatrics. The goal of
the Neuro-Oncology Program continues to be comprehensive care and cuttingedge therapy provided close to home for every patient with a central nervous
system tumor that enters the doors of Children’s Mercy.
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LIVER
TUMOR

LEUKEMIA AND
LYMPHOMA

The Liver Tumor Program is a
multidisciplinary team, which
includes oncology, hepatology,
surgery and liver transplant
services. They work together to give
comprehensive care to children
with liver cancer. Every patient’s
treatment plan is discussed with all
of the disciplines. The coordination
of care begins prior to diagnosis
and continues even after treatment
has been completed.

The Leukemia and Lymphoma Program at Children’s Mercy is comprised of
experts in the diagnosis and management of hematologic malignancies
in children and young adults. Under the direction of Keith August, MD, the
Leukemia and Lymphoma Program is a collaborative effort dedicated to
delivering state-of-the-art clinical care and to generating innovative and
collaborative research efforts. Members are multidisciplinary and include
faculty from the Sections of Oncology, Blood and Marrow Transplant,
Hematopathology, Cytogenetics and the Cancer Genomics program.
Comprehensive patient care meetings occur every two weeks where cases
are reviewed by program members and research efforts are discussed.
Members are actively involved in the development of clinical trials for leukemia
and lymphoma on a national and international level through the Children’s
Oncology Group and other clinical research consortiums.

PATIENT
AND FAMILY
RESEARCH
The Patient and Family Research
Program focuses on individual and
family development, as well issues
that occur across the treatment
trajectory that could compromise
individual and family well-being. This
includes supportive care, symptom
management and psychosocial
needs for all members of the family.
Research initiatives focus on symptom
assessment and management for
adolescents and young adults with
cancer, as well as active engagement
with music during hospitalization for
young children.

HISTIOCYTOSIS
The Histiocytosis Program at Children’s Mercy provides a comprehensive setting for children with a group of rare diseases.
The program is led by J. Allyson Hays, MD, pediatric hematologist/oncologist. It provides current and inclusive clinical
care while collaborating with Jenn Hudson, APRN, and Sara Donnelly, LCSW. Regular, multidisciplinary tumor boards
offer opportunities to discuss management of these challenging diseases with pediatric orthopedic surgeons, pediatric
endocrinologists, pediatric dermatologists and pediatric pathologists familiar with Langerhans cell histiocytosis (LCH),
hemophagocytic lymphohistiocytosis (HLH), sinus histiocytosis with massive lymphadenopathy (SHML)/Rosai Dorfman (RD),
juvenile xanthogranulomatous disease (JXG) and Erdheim-Chester disease (ECD). Children’s Mercy is a member of NACHO,
the North American Consortium for Histiocytosis, and participates in international and national clinical trials to improve the
care of children with histiocytic diseases.
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EXPERIMENTAL
THERAPEUTICS

BONE AND SOFT
TISSUE SARCOMA

The Experimental Therapeutics in Pediatric Cancer Program at
Children’s Mercy was founded in 2010 with a goal of providing
patients with access to early phase clinical trials after relapse
and/or progression has resulted in limited remaining options
for therapy. Over the years, we have developed relationships
with consortiums and pharmaceutical companies, increasing
our ability to have open trials available when they are
needed. On average, 25 clinical trials are open at any time
through our collaboration with Beat Childhood Cancer,
Children’s Oncology Group, Aflac Cancer Center at Emory
Children’s Hospital and industry partners. The Experimental
Therapeutics team includes three physicians, each with their
own specific area of interest including neuro-oncology, solid
tumors, blood cancers and cancer genomics (including ethnic
diversity and its relation to outcome/response). The team
also includes advanced practice nurses and three dedicated
clinical research coordinators, who are vital to our mission
and help to maintain the trials and monitor study patients.

Sarcoma accounts for approximately 15% of all childhood
cancers. Each year, Children’s Mercy treats approximately
15 to 20 children with bone or soft tissue tumors, the most
common of which are osteosarcoma, Ewing sarcoma and
rhabdomyosarcoma. The Bone and Soft Tissue Sarcoma
Program at Children’s Mercy (in collaboration with the
Sarcoma Center at the University of Kansas Cancer Center)
consists of highly-trained specialists in pediatric oncology,
orthopedic oncology, radiation oncology, rehabilitative
medicine, radiology, pathology and interventional radiology,
who focus on providing cutting-edge, family-centered
sarcoma care from diagnosis through treatment and posttherapy monitoring. We believe no child should have to leave
the Kansas City area in order to receive elite, streamlined
sarcoma care, and providing such care is our daily priority.
Additionally, with an expanding panel of collaborative
research opportunities, we are helping to identify the next
generation of sarcoma therapies right here in Kansas City.

In a given year, Experimental Therapeutics treats 15 to 20
children. In addition to the Kansas City region, we have
received a number of outside referrals from centers in Wichita,
St. Louis, Oklahoma, Colorado, Iowa, Arkansas, Illinois and
Texas. With the continued development of the Children’s
Mercy Research Institute and our strong relationship as
consortium partner in the NCI-designated University of
Kansas Cancer Center, we are poised to become a national
leader in innovative cancer treatments for children. Access to
early phase clinical trials has made a significant difference for
children with cancer in Missouri, Kansas and the region.

The Bone and Soft Tissue Sarcoma Program at Children’s
Mercy is led by Joy Fulbright, MD, and Joel Thompson,
MD. The program consists of orthopedic surgery (Howard
Rosenthal, MD, and Kyle Sweeney, MD) radiation oncology
(Ronny Rotondo, MDCM, FRCPC), rehabilitative medicine
(Kimberly Hartman, MD), pediatric oncology, pathology,
interventional radiology and radiology. Our goal is to provide
seamless care coordination from radiation oncology to
pathology and orthopedic surgery, with a multidisciplinary
tumor board and enhanced collaborative research across
disciplines.

The Cancer Immunotherapeutics Program at Children’s Mercy promotes innovative basic and translational investigation designed
to support and launch clinical trials targeting pediatric and adult malignancies. The program supports local investigator-initiated
cancer-directed cellular therapeutics trials at Children’s Mercy and the University of Kansas Medical Center, and participates in
pharmaceutical company-sponsored trials of cellular therapeutics and complex biologics.
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The Survive & Thrive Program offers comprehensive medical
and emotional care to childhood cancer survivors who are
at least two years off treatment and five years from the date
of diagnosis. The program offers four clinics per month, with
more than 300 survivors receiving care. Childhood cancer
survivors are at risk for health problems or late effects from
their cancer and treatment.
Late effects can be physical or emotional, and typically
appear in the second decade of life. The development of
late effects may be influenced by the type of cancer, the
treatment, age at diagnosis and genetic predisposition. An
estimated 95% of childhood cancer survivors will develop
at least one late effect at some point during their life. Late
effects may be preventable or modifiable, which is why
lifelong follow-up is important for all survivors.

(vena cava and aorta) also increase the risk of developing
heart problems.

Examples of late effects that may occur in survivors include
hearing loss, heart dysfunction, infertility, organ dysfunction
(i.e., restrictive or obstructive lung disease), endocrine
dysfunction and development of a second cancer. In
the Survive & Thrive Clinic, survivors are monitored for
development of late effects according to the Children’s
Oncology Group Long-term Follow-up Guidelines. The team
ensures diagnostic tests and labs are completed according
to the guidelines and referrals are made to other specialists
when necessary.

Examples of heart problems that may arise during and
after cancer treatment include heart failure, valvular heart
disease, left ventricular function, elevated cholesterol,
elevated blood pressure and arrhythmia. The collaboration
with the pediatric cardiologists ensures survivors at risk
for cardiac problems receive comprehensive screening,
education and intervention as needed.

The Survive & Thrive team works closely with health care
providers in other specialties to ensure each survivor’s
unique health needs are met. Specialists the team works
closely with include endocrinology, cardiology and
developmental and behavioral sciences.
In 2016, Children’s Mercy launched the Cardio-Oncology
Program to better meet the needs of cancer patients
at risk for developing cardiotoxicity (damage to the
heart and vascular system). Anthracyclines are a class
of chemotherapy drugs used in many pediatric cancer
treatment regimens. Anthracyclines, even in low doses,
increase the risk of heart problems in cancer survivors.
Radiation therapy that involves the heart or major vessels

The Cardio-Oncology program offers specialized treatment
that incorporates screenings by pediatric cardiologists
during cancer treatment and after for survivors. Monitoring
for and addressing cardiac concerns early can reduce the
risk of severe or life-threatening heart problems.

A visit to the Survive & Thrive Clinic includes a thorough
physical exam, recommendations for long-term follow-up
care, education on late effects of cancer treatment and
how to maintain a healthy lifestyle. Assessments by a
dietitian and social worker are included in the survivorship
clinic visit to ensure all needs of the survivor are met.
In conjunction with the hospital-wide Transition to
Adulthood Program, preparation for transition to adult
providers is incorporated into each visit once survivors
reach 15 years of age. The Survive & Thrive team works
with each survivor to teach skills to advocate for their
health care needs and develop an individualized
transition plan. At the time of transition, the team works
with the survivor, family and adult health care providers
to ensure the transfer of care is smooth for everyone
involved in the process.

CA NC ER PRO GR AM S

IMMUNOTHERAPEUTICS

SURVIVE & THRIVE
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CANCER CENTER PHILANTHROPIC DONORS IN 2019:

ACKNOWLEDGEMENT OF 2019
CANCER CENTER

DONORS

The Cancer Center is grateful for the support from our philanthropic donors and
granting organizations:

Paul D. Kempinski, MS, FACHE, President and Chief Executive Officer at
Children’s Mercy, accepts a check for $350,000 from Steve Edwards,
Chairman and Chief Executive Officer of Black & Veatch, at the 2019
Black & Veatch Charity Golf Tournament. The tournament benefited the
cancer genomics program at Children’s Mercy.

Founded by Deliece Hofen when her
son, Braden, was diagnosed with Stage
IV Neuroblastoma, Braden’s Hope for
Childhood Cancer funds research into
targeted therapies that shut down the
activators of childhood cancers. Thanks
to Braden’s Hope, children and families
have real HOPE for long, healthy lives.

Big Slick hosts and celebrity friends
celebrate a record-breaking 10th
Annual Big Slick Celebrity Weekend
benefiting pediatric cancer research
at Children’s Mercy.

Big Slick

Black & Veatch

Braden’s Hope
for Childhood
Cancer

C.W. Titus
Foundation

James M.
Burcalow

DeBruce
Foundation

Noah’s Bandage
Project

Mr. and
Mrs. Henry J.
Massman IV

Laura and Hatch
McCray

Roderick J. and
Jo Anne Cyr
Foundation

Lisa and Dolph
Simons

Victor E.
Speas
Foundation, Bank
of America, N.A.
Trustee

Victor E.
and Caroline E.
Schutte Foundation
Trust E, David W.
Frantze and Bank of
America, N.A., CoTrustees

Bret and Christy
Wilson

Ann and Frank
Uryasz

CANCER CENTER GRANTING ORGANIZATIONS IN 2019:
Alex’s
Lemonade
Stand
Foundation

Braden’s Hope
for Childhood
Cancer

Children’s Mercy
Cancer Center
Auxiliary

Children’s
Oncology
Group

Curing Kids
Cancer

Hyundai Hope
on Wheels

Masonic Cancer
Alliance

Noah’s Bandage
Project

St. Baldrick’s
Foundation

The University
of Kansas
Cancer Center

We are grateful to all of the incredible donors and granting organizations
who are putting children first in the fight against childhood cancer. The donor
commitments listed here represent philanthropic gifts of $50,000+ in fiscal
year 2019 and organizations providing research grant funding to the Cancer
Center in 2019.

DO NO R REC OG NIT ION

46

Founded by six-year-old
Noah Wilson during his
cancer journey, Noah’s
Bandage Project provides
cool and fun bandages to
kids and raises funds for
pediatric cancer research.
Noah’s parents, Deborah
and Scott Wilson, continue
Noah’s Bandage Project
to help kids right here at
Children’s Mercy and all
across the globe.

Ann and Matt
Anthony
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